Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects
Joerg Herrmann(Mayo Clinic), Joshua D. Mitchell(Twitter (United States)), Elena Deych, Anju Nohria(Brigham and Women's Hospital), Ana Barac(Inova Fairfax Hospital), Jennifer Liu(Memorial Sloan Kettering Cancer Center), Andrés J. Daniele(Asociación por los Derechos Civiles), Ariane Vieira Scarlatelli Macedo(Santa Casa Hospital), Daniel J. Lenihan(Saint Francis Medical Center), Susan Dent(Government of the United States of America), Aaron L. Sverdlov(Hunter New England Local Health District), Giselle Alexandra Suero‐Abreu(Massachusetts General Hospital), Michael G. Fradley(University of South Florida), Joseph R. Carver(Hospital of the University of Pennsylvania), Charles Porter(University of Kansas Medical Center), Tienush Rassaf(West German Heart and Vascular Center Essen), Darryl P. Leong(Population Health Research Institute), Dae Hyun Lee(University of South Florida), Meghan J. Mooradian(Massachusetts General Hospital), Tomas G. Neilan(Albert Einstein College of Medicine), Paaladinesh Thavendiranathan(Toronto General Hospital), Teresa López‐Fernández(Hospital Universitario La Paz), Alexander R Lyon(Royal Brompton Hospital), Richard K. Cheng(University of Washington)
Cited by 10
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
|European Journal of Heart Failure|2016|1.8k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k